Conference Coverage

Psoriatic arthritis treatment: “We’re not doing so well”

Publish date: March 7, 2018

 

EXPERT ANALYSIS FROM RWCS 2018

Pages

Recommended Reading

CV risk factors go undiagnosed, untreated in many psoriatic patients
MDedge Rheumatology
Get ready for certolizumab for psoriasis
MDedge Rheumatology
ACR sounds more welcoming tone in new biosimilars position paper
MDedge Rheumatology
Here comes bimekizumab, the newest IL-17 inhibitor
MDedge Rheumatology
Risankizumab outpaced ustekinumab for complete clearance of plaque psoriasis
MDedge Rheumatology
Experts review the year in rheumatology ... and what lies ahead
MDedge Rheumatology
Biologics have best chance of achieving PASI 90 in psoriasis
MDedge Rheumatology
Ustekinumab quells aortic inflammation in patients with severe psoriasis
MDedge Rheumatology
Could guselkumab be a disease-modifying agent in plaque psoriasis?
MDedge Rheumatology
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
MDedge Rheumatology